Reversal reaction in multibacillary leprosy patients following MDT with and without immunotherapy with a candidate for an antileprosy vaccine, Mycobacterium w.
Immunotherapy with a candidate for an antileprosy vaccine, Mycobacterium w, was given in addition to standard multidrug therapy (MDT) to 53 multibacillary lepromin negative patients belonging to BB, BL and LL types of leprosy (vaccine group). An equal control group received MDT and injections of micronized starch as placebo. Both the vaccine and placebo were administered intradermally every 3 months. The patients were evaluated at determined intervals by clinical, bacteriological and histopathological parameters and lepromin testing. Reactional episodes were analysed with reference to incidence, onset, frequency and severity during and after release from treatment (RFT). Incidence of reversal reaction (RR) was marginally higher in the vaccine group (22.6% vaccine group vs 15% control group). All cases with a history of downgrading type 1 reaction developed RR during therapy. Most episodes occurred within the 1st year of the commencement of therapy--50% developing within 3 months. Late reversal reaction (after RFT) were observed in 3.8% of cases in both groups, and 50% of the reactors in the control group and 33% in the vaccine group had repeated reactional episodes. Incidence of neuritis associated with RR as well as isolated neuritis was similar in both groups.
Kar
H K
HK
Department of Skin, STD and Leprosy, Dr. RML Hospital, New Delhi.
Sharma
A K
AK
Misra
R S
RS
Beena
K R
KR
Zaheer
S A
SA
Mukherjee
R
R
Mukherjee
A
A
Parida
S K
SK
Walia
R
R
Nair
N S
NS
D001428:Bacterial Vaccines / Q000009:adverse effects / Q000627:therapeutic use*; D002991:Clofazimine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003622:Dapsone / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D007917:Leprostatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007918:Leprosy / Q000473:pathology* / Q000628:therapy*; D009443:Neuritis / Q000209:etiology; D012293:Rifampin / Q000008:administration & dosage; D016037:Single-Blind Method
D001428:Bacterial Vaccines; D007917:Leprostatic Agents; C060596:anti-leprosy vaccine; D003622:Dapsone; D002991:Clofazimine; D012293:Rifampin